William S. Marth steps down as president and CEO of Teva Americas

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and we will feature it here each Friday.

William S. Marth steps down as president and CEO of Teva Americas

Teva Pharmaceutical Industries ($TEVA) made several changes to its executive management team this week, starting with William S. Marth stepping down as president and CEO of Teva Americas. Marth will leave his posts immediately and retire at the end of next year. He will serve as senior adviser to Teva CEO Jeremy Levin until his retirement. Allan Oberman, Teva's senior vice president of North America Generic Pharmaceuticals, will move up to president and CEO of Teva Americas Generics. The company also appointed Jill DeSimone to the newly created position of senior vice president and general manager of Teva Global Women's Health. Release | Story

William S. Marth--Teva Pharmaceutical Industries
Marth retired as president and CEO of Teva Americas.

John A. Orwin--Array BioPharma
Affymax CEO Orwin joined Array's board of directors.


> Array BioPharma ($ARRY) announced that John A. Orwin, CEO of Affymax ($AFFY), joined Array's board of directors. Release

> AIMM Therapeutics appointed Jan de Vries as CEO and John Womelsdorf as vice president of business development. Release

> Apricus Biosciences ($APRI) announced that Bassam Damaj has resigned as a director, president and CEO of the company. Steve Martin, senior vice president and chief financial officer, will serve as interim CEO. Release

> PTC Therapeutics appointed Geoffrey McDonough to its board of directors. Release

> PuraMed BioScience appointed Richard J. Berman as investment consultant. Release

> Vical ($VICL) appointed Mammen P. "Anza" Mammen Jr. as vice president of clinical vaccines. Release

> Nextera appointed Thomas Anderson as CEO. Release

> Sarepta Therapeutics ($SRPT) named Sandesh Mahatme as senior vice president and CFO, and David Tyronne Howton as senior vice president and general counsel. Release

> Insmed ($INSM) appointed Andrew Drechsler as CFO. Release

> Arbor Pharmaceuticals appointed Thom Rowland as vice president of commercial operations. Release

> Cornerstone Therapeutics ($CRTX) announced the appointment of Alastair McEwan as CFO. Release

Medical Devices

> Pathwork Diagnostics appointed Lee McCracken as CEO. Release

> Becton, Dickinson ($BDX) appointed William A. Kozy as chief operating officer. Release

> Mindray Medical ($MR) announced that Xu Hang resigned as co-CEO, but will continue to serve as the company's chairman. Li Xiting was appointed CEO and president. Release


> The National Pharmaceutical Council elected Daiichi Sankyo CEO John Gargiulo as chairman of the board. Release

> Novartis ($NVS) announced that Marjorie Yang has decided not to seek re-election to the company's Board of Directors. Her term ends in 2013. Release

Biotech IT

Medidata Solutions ($MDSO) named Eileen Schloss executive vice president of human resources. Release

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Life sciences companies have pivoted quickly during COVID-19 - Syneos Health® is supporting more than 80 active COVID-19 projects, including vaccines.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.